Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk [Yahoo! Finance]
Fulcrum Therapeutics, Inc. (FULC)
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
7.1% to 19.3% over 12 weeks, ?12.2), improvement in hemolysis markers, and an early vaso-occlusive crisis (VOC) reduction signal (6 VOCs observed vs. 16 expected; 7 of 12 patients had no VOC during treatment). Regulatory path : Fulcrum plans an FDA end-of-phase meeting in Q2 and intends to start a 200–300 patient registrational trial in H2, with a planned interim 6-month HbF analysis in ~half the cohort to support a potential accelerated approval. Safety, focus and funding : Hematologic safety signals include decreased reticulocytes and increased total hemoglobin with no broad cytopenias aside from one parvovirus-related case; the company is refocusing on sickle cell, has discontinued its DBA program, and reports cash runway into 2029 with U.S. commercialization preferred and likely ex-U.S. partnerships. Interested in Fulcrum Therapeutics, Inc.? Here are five stocks we like better. Fulcrum Therapeutics (NASDAQ:FULC) executives highlighted what they described as strong physicia
Show less
Read more
Impact Snapshot
Event Time:
FULC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FULC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FULC alerts
High impacting Fulcrum Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FULC
News
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare ConferenceGlobeNewswire
- Fulcrum Therapeutics move lower ‘overdone,' says Stifel [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics (FULC) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
FULC
Earnings
- 2/24/26 - In-Line
FULC
Sec Filings
- 2/24/26 - Form S-8
- 2/24/26 - Form 10-K
- 2/24/26 - Form 8-K
- FULC's page on the SEC website